NCT01610427

Study to Optimize the Quality of Samples for Cell-mediated Immunity (CMI) in ART-naïve HIV-1-infected Subjects

Optimizing the Quality of Samples Used for the Evaluation of Cell-mediated Immune (CMI) Responses in Antiretroviral Therapy (ART)-naïve Human Deficiency Virus Type 1 (HIV-1)-Infected Subjects

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: GlaxoSmithKline · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to investigate a combined set of parameters deemed to impact the quality of CMI analyses in terms of the proportion of viable lymphocytes in antiretroviral therapy-naïve HIV-1 infected subjects.

Detailed description

This study will address the respective and combined impact of (i) timing between blood collection and peripheral blood mononuclear cells (PBMC) processing \["time-to-process"\] and (ii) timing of PBMC resting before stimulation \["resting -time"\].

Conditions

• AIDS
• AIDS Vaccines

Interventions

Type	Name	Description
PROCEDURE	Blood sample collection	Blood samples will be collected in all subjects at two time points, at the Screening Visit (Day 0) and at the Sample Collection Visit (Day 15)

Timeline

• Start date: 2012-06-25
• Primary completion: 2012-10-30
• Completion: 2012-10-30
• First posted: 2012-06-04
• Last updated: 2020-04-24
• Results posted: 2020-04-24

Locations

1 site across 1 country: Belgium